Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-02-16 00:00:00 ET · period of report 2024-02-14 · accession 0000875320-24-000064 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-02-16 | 2024-02-14+ | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | S - Sale | $419.10 | -9,011 | 17.9K | -33% | -$3.78M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-14 | S | D | 4,356 | $419.04 | 22,551 | D | — | — | (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F3) Open market sales reported on this line occurred at a weighted average price of $419.04 (range $419.00 to $419.38). |
| 2 | Common | Common Stock | 2024-02-15 | S | D | 4,655 | $419.16 | 17,896 | D | — | — |